Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Amgen Inc.NASDAQ: AMGN

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow declines year over year

Q2 FY2026 financing cash flow of $1.48B (cash outflow) fell 44.6% year over year, ahead of the -65.2% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +39.1% a year.

Context

  • Financing cash flow amounted to 29.6% of revenue in FY2025, up 1.4 pp from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -44.6% holds above the trailing-twelve-month pace of -65.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.48B-203.2% QoQ
Last fiscal yearDec 2025
-$10.86B+15.3% YoY
LTMJun 2026
-$4.13B-65.2% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.6%——
1 year+15.3%——
3-year CAGR+39.1%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(10.86B) USD
Year-over-year change
-15.3%

Financing Cash Flow vs competitors

How AMGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -65.2% is the lowest of 10, against a peer median of +40.7%.
  • Financing cash flow amounts to 10.8% of revenue for AMGN, versus a peer median of 9.3%.
AMGN Competitors
Financing Cash Flow for AMGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$18.15B USD+229.4%-14.5%18.3%
ABBVAbbVie Inc.LTM Jun 2026$12.89B USD-7.3%-19.9%20.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$11.71B USD+40.7%-15.2%23.8%
PFEPfizer Inc.LTM Jun 2026$8.4B USD-53.8%-11.4%13.2%
MRKMerck & Co., Inc.LTM Jun 2026$6.17B USD+141.8%-40.5%9.3%
AZNAstraZeneca PLCLTM Sep 2026$5.39B USD+9.1%+3.4%8.7%
AMGNAmgen Inc.LTM Jun 2026$4.13B USD-65.2%+39.1%10.8%
LLYEli Lilly and CompanyLTM Jun 2026$2.61B USD+2060.9%-25.8%3.3%
GSKGSK plcLTM Jun 2026£2.53B GBP-29.6%—7.6%
NVSNovartis AGLTM Jun 2026$472.2M USD+102.8%-10.1%0.8%
Peer median (excluding AMGN) —+40.7%-14.9%9.3%

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.89B6.55B6.72B4.09B7.71B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
Deferred Income Tax(453M)(1.2B)(1.27B)(1.23B)(721M)
Stock-Based Compensation341M401M431M530M494M
Change in Working Capital(1.19B)(733M)(484M)2.37B(1.98B)
Accounts Receivables(429M)(746M)(1.02B)441M(2.68B)
Inventory(165M)(742M)491M2.53B886M
Accounts Payables(69M)154M(402M)312M428M
Other Working Capital(531M)601M442M(920M)(616M)
Other Non-Cash Items1.28B1.28B(991M)141M(715M)
Operating Cash Flow9.26B9.72B8.47B11.49B9.96B
Capital Expenditures(880M)(936M)(1.11B)(1.1B)(1.86B)
Acquisitions (Net)(2.69B)(3.73B)(26.99B)0(53M)
Purchases of Investments(8.9B)(2.59B)(1M)00
Sales of Investments13.23B1.22B1.67B00
Other Investing Activities(35M)(12M)225M50M(32M)
Investing Cash Flow733M(6.04B)(26.2B)(1.05B)(1.94B)
Debt Repayment795M6.62B25.68B(4.26B)(5.68B)
Common Stock Issued00000
Common Stock Repurchased(4.98B)(6.36B)0(200M)0
Dividends Paid(4.01B)(4.2B)(4.56B)(4.83B)(5.12B)
Other Financing Activities(78M)(103M)(72M)(124M)(52M)
Financing Cash Flow(8.27B)(4.04B)21.05B(9.42B)(10.86B)
Effect of Forex Changes00000
Net Change in Cash1.72B(360M)3.32B1.03B(2.84B)
Free Cash Flow8.38B8.79B7.36B10.39B8.1B

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.